Sotalol (DB00489): A Comprehensive Monograph on its Pharmacology, Clinical Utility, and Safety Profile

Executive Summary

Sotalol is an antiarrhythmic agent with a unique pharmacological profile, functioning as both a non-selective beta-adrenergic antagonist (Vaughan Williams Class II) and a potent potassium channel blocker (Vaughan Williams Class III). This dual mechanism of action endows it with efficacy in managing a range of cardiac arrhythmias, with primary US Food and Drug Administration (FDA) approvals for the treatment of life-threatening ventricular arrhythmias and the maintenance of normal sinus rhythm in patients with highly symptomatic atrial fibrillation or atrial flutter.[1] First synthesized in 1960, sotalol is administered as a racemic mixture, with its distinct enantiomers contributing different aspects of its overall effect: the l-isomer provides virtually all of the beta-blocking activity, while both isomers possess comparable Class III effects.[3]

The clinical utility of sotalol is fundamentally defined by a central paradox: its therapeutic efficacy in suppressing arrhythmias is inextricably linked to a significant, dose-dependent proarrhythmic risk. The primary safety concern is the prolongation of the QT interval, which can precipitate a life-threatening polymorphic ventricular tachycardia known as Torsade de Pointes (TdP).[5] This risk is magnified by the drug's pharmacokinetic and pharmacodynamic properties, including a phenomenon known as "reverse use-dependence," where its proarrhythmic potential is greatest at slower heart rates.[1] Furthermore, sotalol is eliminated almost exclusively by the kidneys, making its clearance directly dependent on renal function.[7] Consequently, renal impairment leads to drug accumulation and a markedly increased risk of toxicity.

These characteristics have necessitated the development of stringent clinical protocols for its use. The initiation or dose escalation of sotalol therapy is mandated to occur within a hospital setting, allowing for a minimum of three days of continuous electrocardiographic (ECG) monitoring and cardiac resuscitation availability.[9] Patient selection is paramount, requiring careful assessment of baseline QT interval, renal function, and electrolyte status, with numerous contraindications designed to exclude individuals at high risk of adverse events. This comprehensive monograph provides an exhaustive analysis of sotalol's chemical properties, dual mechanisms of action, clinical pharmacokinetics, therapeutic applications, and detailed safety profile, situating it within the contemporary antiarrhythmic armamentarium as a potent but demanding therapeutic agent.

Section 1: Chemical and Pharmaceutical Profile

The foundational understanding of sotalol's pharmacological behavior begins with its precise chemical identity, physical characteristics, and the critical stereochemistry that dictates its dual-action profile.

1.1 Nomenclature, Identifiers, and Structural Data

Sotalol is a synthetic compound belonging to the methanesulfonanilide class.[2] Its unambiguous identification across scientific, regulatory, and clinical domains is ensured by a standardized set of nomenclature and chemical identifiers.

The systematic chemical name for sotalol is N-[1-hydroxy-2-[(1-methylethyl)amino]ethyl]phenyl]methanesulfonamide.[4] It is also referred to by its Chemical Abstracts Service (CAS) Registry Number, 3930-20-9.[3] In pharmacological databases, it is cataloged under identifiers such as DrugBank ID DB00489.[2]

Its molecular formula is C12​H20​N2​O3​S, corresponding to a molecular weight of 272.36 g/mol.[3] The molecular structure is precisely defined by standard chemical notations, including the Simplified Molecular-Input Line-Entry System (SMILES) string

CS(NC1=CC=C(C(O)CNC(C)C)C=C1)(=O)=O and the International Chemical Identifier Key (InChIKey) ZBMZVLHSJCTVON-UHFFFAOYSA-N.[3] These structural data provide a complete chemical fingerprint essential for research and computational modeling.

1.2 Physicochemical Properties and Formulation Characteristics

Sotalol's behavior in biological systems is heavily influenced by its physical and chemical properties. It exists as a pale yellow to light yellow solid at room temperature.[3] It has a distinct melting point of 206.5-207 °C and a predicted boiling point of approximately 443.3 °C.[3]

A key characteristic of sotalol is its hydrophilic nature. It is soluble in water, propylene glycol, and ethanol but only slightly soluble in chloroform.[3] This high water solubility is a defining feature that impacts its pharmacokinetic profile, contributing to its high oral bioavailability and limited penetration of the blood-brain barrier.[1] Based on its high solubility and high permeability, sotalol is classified as a Biopharmaceutics Classification System (BCS) Class 1 drug, a category reserved for compounds that are well-absorbed and whose absorption rate is primarily governed by gastric emptying.[3] The compound has two dissociation constants, with pKa values of 8.2 and 9.8 at 25 °C.[3]

From a pharmaceutical standpoint, sotalol is known to be hygroscopic, meaning it readily absorbs moisture from the atmosphere. This necessitates storage in a freezer at -20 °C under an inert atmosphere to maintain its stability.[3] It is commercially available in several formulations, including oral tablets (marketed under brand names such as Betapace®, Betapace AF®, and Sorine®), an oral solution (Sotylize®), and an intravenous solution for injection, providing flexibility for administration in both outpatient and inpatient settings.[4]

1.3 Stereochemistry: The Distinct Roles of d- and l-Sotalol

Sotalol contains a chiral center and therefore exists as two distinct stereoisomers, or enantiomers: d-sotalol and l-sotalol. The clinically available formulations consist of a racemic mixture, meaning they contain equal amounts of both enantiomers.[4] This formulation as a racemate is not a matter of manufacturing convenience but rather a deliberate pharmacological strategy, as the two isomers possess markedly different and complementary pharmacological activities that together define the drug's unique clinical profile.

The l-enantiomer is responsible for virtually all of the drug's non-selective beta-adrenergic blocking (Vaughan Williams Class II) activity.[3] In contrast, the d-enantiomer has a very low affinity for beta-adrenergic receptors, estimated to be 30 to 60 times lower than that of the l-isomer.[3]

Conversely, both the d- and l-isomers exhibit potent and comparable Class III antiarrhythmic effects, which are derived from the blockade of cardiac potassium channels.[3] This stereospecificity is the cornerstone of sotalol's pharmacology. The administration of the racemate results in a composite drug action. The hemodynamic effects, such as the reduction in heart rate and blood pressure, are primarily driven by the l-isomer's beta-blockade. The primary electrophysiological effects responsible for rhythm control, namely the prolongation of the cardiac action potential, are driven by both isomers. This inherent duality distinguishes sotalol from a simple combination of a standard beta-blocker and a separate Class III agent, as the fixed 1:1 stereoisomeric ratio defines its specific and inseparable risk-benefit profile.

Table 1: Key Physicochemical and Identification Properties of Sotalol

Property	Value / Description	Source(s)
DrugBank ID	DB00489	2
CAS Number	3930-20-9	3
Chemical Name	N-[1-hydroxy-2-[(1-methylethyl)amino]ethyl]phenyl]methanesulfonamide	4
Molecular Formula	C12​H20​N2​O3​S	3
Molecular Weight	272.36 g/mol	3
Physical Form	Pale yellow to light yellow solid	3
Melting Point	206.5-207 °C	3
Solubility	Soluble in water and ethanol; slightly soluble in chloroform	3
pKa	pK1 8.2, pK2 9.8 (at 25 °C)	3
BCS Class	Class 1 (High Solubility, High Permeability)	3
Stability	Hygroscopic; requires storage at -20 °C under inert atmosphere	3
SMILES	CS(NC1=CC=C(C(O)CNC(C)C)C=C1)(=O)=O	3
InChIKey	ZBMZVLHSJCTVON-UHFFFAOYSA-N	3

Section 2: Comprehensive Pharmacological Profile

Sotalol's clinical effects are a direct result of its unique dual-class mechanism, which combines the properties of two distinct categories of antiarrhythmic agents. This section provides a detailed mechanistic explanation of its actions at the molecular, cellular, and organ levels.

2.1 Mechanism of Action: A Unique Dual-Class Antiarrhythmic Agent

Sotalol is classified as both a Vaughan Williams Class II and Class III antiarrhythmic agent, a distinction that sets it apart from most other drugs in its category.[4]

2.1.1 Class II Activity: Non-selective Beta-Adrenergic Blockade

The Class II activity of sotalol arises from its function as a non-selective beta-adrenergic receptor antagonist, meaning it competitively blocks both β1- and β2-adrenergic receptors.[3] This action, primarily attributed to the l-enantiomer, is devoid of any intrinsic sympathomimetic (partial agonist) or membrane-stabilizing activity.[4]

At the molecular level, beta-blockade prevents the binding of endogenous catecholamines like epinephrine and norepinephrine to their receptors on cardiac myocytes. This inhibition disrupts the downstream signaling cascade, preventing the G-protein-mediated activation of adenylyl cyclase and the subsequent production of the second messenger cyclic AMP (cAMP).[14] Reduced intracellular cAMP levels lead to decreased activation of protein kinase A and a subsequent reduction in calcium influx through L-type calcium channels. The resulting decrease in intracellular calcium concentration has two major consequences: a negative chronotropic effect, which slows the rate of spontaneous depolarization in the sinoatrial (SA) node and thus reduces heart rate, and a negative inotropic effect, which decreases the force of myocardial contraction.[14]

The dose-response relationship for this beta-blocking effect is well-characterized. Significant beta-blockade is observed at oral doses as low as 25 mg, becomes half-maximal at approximately 80 mg/day, and reaches its maximal effect at doses between 320 and 640 mg/day.[4] This action is responsible for many of sotalol's therapeutic effects, including rate control and blood pressure reduction, as well as some of its characteristic side effects like bradycardia, fatigue, and bronchospasm in susceptible individuals.[16]

2.1.2 Class III Activity: Inhibition of the Rapid Delayed-Rectifier Potassium Current (IKr​/hERG)

Sotalol's defining Class III action, which is responsible for its primary rhythm-control properties, is the potent and competitive inhibition of specific cardiac potassium channels.[1] This effect is mediated by both the d- and l-enantiomers. The specific target is the channel that conducts the rapid component of the delayed rectifier potassium current, known as

IKr​.[1] These channels are protein complexes encoded by the human Ether-à-go-go-Related Gene (hERG), also designated as KCNH2.[2]

The IKr​ current plays a critical role in Phase 3 of the cardiac action potential, which is the repolarization phase where the cell membrane potential returns to its negative resting state. By blocking this outward flow of potassium ions, sotalol delays repolarization. This has the direct effect of prolonging the duration of the cardiac action potential (APD).[1] A longer APD, in turn, leads to a longer effective refractory period (ERP)—the period during which the myocyte cannot be re-excited. This effect occurs in atrial, Purkinje, and ventricular tissues, as well as in atrioventricular accessory pathways.[4] By prolonging the ERP, sotalol makes the cardiac tissue less susceptible to premature stimuli and disrupts the re-entrant circuits that underlie many tachyarrhythmias.

Unlike its beta-blocking action, the Class III effects of sotalol are not clinically significant at very low doses. They typically emerge at daily oral doses of 160 mg and above.[1] This non-parallel dose-response relationship is of critical clinical importance. It signifies that as the dose is titrated upwards to achieve rhythm control, the pharmacological profile of the drug fundamentally shifts from that of a primary beta-blocker to that of a potent Class III agent. This transition is accompanied by a corresponding and significant increase in the risk of its primary toxicity: excessive QT prolongation and TdP.

2.1.3 Clinical Implications of Reverse Use-Dependence

A critical pharmacodynamic property of sotalol is "reverse use-dependence".[1] This term describes the phenomenon where its potassium channel-blocking effect, and therefore its APD-prolonging action, is most pronounced at slower heart rates and diminishes as the heart rate increases.[1]

This feature has profound clinical implications and is the key mechanistic link explaining why bradycardia is a major independent risk factor for sotalol-induced TdP. At slower heart rates, the diastolic interval is longer, which allows more time for sotalol molecules to bind to the hERG channel in its susceptible (open or inactivated) states, thereby enhancing the block. This enhanced block leads to greater APD prolongation, which manifests on the surface ECG as a longer QT interval. This excessive QT prolongation creates the electrophysiological substrate for early afterdepolarizations (EADs), which are the cellular triggers for TdP. Sotalol's pharmacology thus creates a dangerous positive feedback loop: its own Class II beta-blocking effect can induce or worsen bradycardia, which in turn potentiates its proarrhythmic Class III effect, maximizing the risk of a lethal arrhythmia precisely when the heart is beating slowly.

2.2 Pharmacodynamic Effects

The dual mechanisms of action translate into distinct and measurable effects on cardiac electrophysiology and hemodynamics.

2.2.1 Electrophysiological Impact on the Cardiac Action Potential

The combined Class II and Class III effects of sotalol produce characteristic changes on the surface ECG, which serves as the primary tool for monitoring both its therapeutic efficacy and its potential for toxicity.

• Class II Effects: The beta-blocking action increases the sinus cycle length, resulting in a slower resting heart rate (sinus bradycardia). It also slows conduction through the atrioventricular (AV) node, which can manifest as a prolongation of the PR interval on the ECG.[4]
• Class III Effects: The potassium channel blockade directly leads to a dose- and concentration-dependent prolongation of the QT interval.[17] This prolongation reflects the delayed ventricular repolarization and is the hallmark of the drug's Class III action.

The prolongation of the ERP in atrial muscle, ventricular muscle, and accessory pathways is the fundamental basis for its efficacy in terminating and preventing re-entrant tachyarrhythmias, such as those seen in atrial fibrillation and ventricular tachycardia.[4]

2.2.2 Hemodynamic Consequences

Sotalol's beta-blocking properties have significant hemodynamic effects. It produces a reliable reduction in both systolic and diastolic blood pressures.[4] The combination of its negative chronotropic (rate-slowing) and negative inotropic (contractility-reducing) effects leads to a decrease in myocardial oxygen demand and can also reduce cardiac output.[8]

While these effects can be beneficial in conditions like hypertension or angina, they also pose a risk. In patients with marginal cardiac compensation or pre-existing systolic dysfunction, the reduction in contractility and heart rate can precipitate or worsen congestive heart failure.[4] This necessitates extreme caution when using sotalol in patients with a history of heart failure and is the basis for several of its contraindications.

Section 3: Clinical Pharmacokinetics (ADME)

The clinical pharmacokinetics of sotalol—its absorption, distribution, metabolism, and excretion (ADME)—are characterized by a profile that can be described as simple but unforgiving. Its predictability in individuals with normal organ function is offset by its extreme sensitivity to changes in renal clearance, a feature that dictates its entire safety and dosing paradigm.

3.1 Absorption and Bioavailability

Following oral administration, sotalol is rapidly and almost completely absorbed from the gastrointestinal tract. Its oral bioavailability is very high, ranging from 90% to 100%.[1] A key feature contributing to this high bioavailability is the absence of any significant first-pass hepatic metabolism.[1]

Peak plasma concentrations (Cmax​) are typically reached between 2.5 and 4 hours after an oral dose.[1] With consistent twice-daily dosing, steady-state plasma concentrations are achieved within 2 to 3 days, a timeframe that corresponds to approximately five to six elimination half-lives.[4] The absorption of sotalol can be significantly reduced by the concurrent ingestion of food, particularly milk and dairy products. For this reason, it is recommended that sotalol be administered on an empty stomach, either 1 to 2 hours before meals.[15] The high and predictable bioavailability means that plasma levels are directly proportional to the administered dose, which simplifies therapeutic management in patients with normal renal function.

3.2 Distribution, Volume, and Protein Binding

As a hydrophilic (water-soluble) compound, sotalol has distinct distribution characteristics. Its low lipophilicity results in minimal penetration across the blood-brain barrier, which may contribute to a lower incidence of central nervous system side effects (e.g., vivid dreams, confusion) compared to more lipophilic beta-blockers like propranolol.[1]

Sotalol is not significantly bound to plasma proteins, a feature that further enhances its pharmacokinetic predictability.[17] The lack of protein binding means that its free, pharmacologically active concentration is not affected by conditions that alter plasma protein levels, such as malnutrition, liver disease, or critical illness. The apparent volume of distribution (

Vd​) has been estimated to be approximately 5.6 L/kg, indicating distribution into tissues beyond the plasma compartment, including the heart, liver, and kidneys.[1] Sotalol is also known to cross the placenta and is excreted in breast milk.[17]

3.3 Metabolism and Biotransformation

One of the most critical pharmacokinetic features of sotalol is that it is not metabolized in the body.[1] It is excreted from the body completely unchanged and has no active or inactive metabolites.[1] This absence of hepatic metabolism means that liver function has no impact on its clearance. It also eliminates the risk of drug-drug interactions mediated by the cytochrome P450 (CYP450) enzyme system. While one database lists sotalol as a theoretical substrate for CYP2D6, the overwhelming clinical and pharmacological evidence confirms that hepatic metabolism is negligible and clinically irrelevant.[1] This complete reliance on the kidneys for elimination is the central pillar of its pharmacokinetic profile.

3.4 Excretion and the Critical Role of Renal Function

Sotalol is eliminated almost exclusively by the kidneys. More than 80% of an administered dose is excreted unchanged in the urine, primarily through glomerular filtration with a small component of tubular secretion.[1]

In individuals with normal renal function, the elimination half-life (t1/2​) is long, typically ranging from 7 to 20 hours.[1] This long half-life allows for convenient twice-daily dosing regimens.[15]

The single most important factor governing sotalol's pharmacokinetics is renal function. There is a direct, linear relationship between sotalol clearance and creatinine clearance (CrCl).[7] As renal function declines, the elimination half-life is prolonged dramatically. In anuric patients, the half-life can extend up to 69 hours, leading to significant drug accumulation with standard dosing intervals.[7] This accumulation directly increases plasma concentrations, which in turn magnifies the risk of all dose-dependent adverse effects, most notably severe bradycardia and TdP. This unforgiving, mechanical link between renal function and drug exposure is why the calculation of CrCl is an absolute prerequisite for safe sotalol prescribing and is the primary determinant of its dosing intervals and contraindications.

Table 2: Summary of Sotalol's Pharmacokinetic Parameters

Parameter	Value / Description	Source(s)
Bioavailability (Oral)	90-100%	1
Time to Peak Plasma Concentration (Tmax​)	2.5 - 4 hours	1
Time to Steady State	2 - 3 days	4
Effect of Food	Absorption reduced by food, especially dairy; take 1-2 hours before meals	25
Plasma Protein Binding	Not significant	17
Volume of Distribution (Vd​)	Approx. 5.6 L/kg	26
Metabolism	Not metabolized; no active metabolites	1
Primary Route of Excretion	Renal (>80% excreted unchanged in urine)	1
Elimination Half-life (t1/2​)	7 - 20 hours (in normal renal function)	1
Effect of Renal Impairment	Half-life is directly proportional to decline in creatinine clearance; significant accumulation occurs	7

Section 4: Clinical Applications and Therapeutic Efficacy

Sotalol's unique dual-action pharmacology translates into specific clinical applications for the management of cardiac arrhythmias. Its indications are narrowly defined by regulatory bodies to balance its therapeutic benefits against its significant potential for harm.

4.1 Approved Indications

The US Food and Drug Administration (FDA) has approved sotalol for two primary indications, both of which involve serious disturbances of cardiac rhythm. The language used in these approvals consistently emphasizes a high threshold for use, reflecting a regulatory awareness of the drug's inherent risks. This positions sotalol not as a first-line agent for minor arrhythmias but as a potent tool reserved for situations where the therapeutic benefit is judged to clearly outweigh the potential for fatal proarrhythmia.

4.1.1 Management of Life-Threatening Ventricular Arrhythmias

Sotalol is indicated for the treatment of documented, life-threatening ventricular arrhythmias, such as sustained ventricular tachycardia (VT).[1] Clinical studies have demonstrated its superiority to placebo in reducing the burden of ventricular ectopy, including premature ventricular complexes (VPCs) and non-sustained VT.[4] However, it is important to note that, in line with findings for many antiarrhythmic drugs, sotalol has not been shown to enhance survival in patients with life-threatening ventricular arrhythmias.[29] Therefore, its use in this context is aimed at reducing arrhythmia burden, preventing hemodynamic compromise, and alleviating symptoms, rather than providing a mortality benefit.

4.1.2 Maintenance of Normal Sinus Rhythm in Atrial Fibrillation and Flutter

Sotalol is also indicated for the maintenance of normal sinus rhythm, specifically for delaying the time to recurrence of arrhythmia, in patients with a history of highly symptomatic atrial fibrillation (AF) or atrial flutter (AFL) who are currently in sinus rhythm.[1] The emphasis on "highly symptomatic" is a critical qualifier. The FDA explicitly advises that sotalol should be reserved for patients in whom the arrhythmia causes significant symptoms and that it should generally not be used for patients with paroxysmal AF that is infrequent or easily reversed by simple maneuvers.[9] This indication underscores the need for a careful risk-benefit assessment by the prescribing clinician, who must document that the patient's condition meets this high severity threshold.

4.2 Off-Label and Investigational Uses

Beyond its approved indications, sotalol is utilized in clinical practice for several off-label applications, leveraging its broad antiarrhythmic and beta-blocking properties. These uses include:

• Pharmacological Cardioversion of AF: While less effective than electrical cardioversion or some other agents, sotalol is sometimes used in an attempt to chemically convert recent-onset AF to sinus rhythm.[1]
• Postoperative Atrial Fibrillation: It is used for the management and prevention of AF following cardiac surgery.[1]
• Supraventricular Tachycardia (SVT): Sotalol is effective in managing various forms of SVT, including those involving accessory pathways as seen in Wolff-Parkinson-White (WPW) syndrome.[1]
• Fetal Arrhythmias: In specialized centers, sotalol is used in transplacental therapy to treat fetal SVT and AF, often in combination with digoxin, with reports of high success rates.[1]
• Essential Tremor: Due to its non-selective β2-receptor blockade, sotalol has shown some potential efficacy in reducing the symptoms of essential tremor, though this remains an off-label use.[14]

4.3 Analysis of Key Clinical Trial Data

The evidence base for sotalol's use is supported by numerous clinical trials and registries. The Cardiac Arrest in Seattle: Conventional Versus Amiodarone Drug Evaluation (CASCADE) trial (NCT00000464) included sotalol in its comparison of antiarrhythmic drugs for the prevention of cardiac arrest.[31] The Sotalol-Amiodarone Fibrillation Efficacy Trial (SAFE-T) was a landmark study that directly compared the efficacy and safety of sotalol and amiodarone for maintaining sinus rhythm in patients with persistent AF.[32] More recent studies, such as the Prospective Evaluation Analysis and Kinetics of IV Sotalol (PEAKS) registry (NCT05247320), have focused on optimizing the administration of intravenous sotalol to ensure safety and efficacy.[26] The BETAFLEC-CHIOS registry (NCT04991896) has explored the combination of beta-blockers, including sotalol, with other antiarrhythmic agents like flecainide for paroxysmal AF.[35] These trials collectively form the evidentiary foundation upon which clinical guidelines and prescribing practices are built.

Section 5: Dosage, Administration, and Clinical Monitoring

The safe and effective use of sotalol is critically dependent on a rigorous and highly protocolized approach to its administration. The process of initiating and titrating sotalol is as important as the selection of the dose itself, a clinical reality born from its high-risk pharmacology.

5.1 Dosing Regimens: Oral and Intravenous Formulations

Sotalol is available in multiple formulations to accommodate different clinical scenarios.[4]

• Oral Dosing:
• For Ventricular Arrhythmias: The recommended initial oral dose is typically 80 mg administered twice daily (BID).[7] The dose can be gradually increased in increments of 80 mg per day at intervals of no less than 3 days to allow the drug to reach steady-state plasma concentrations. The usual therapeutic range is 160 to 320 mg per day, divided into two doses. In patients with refractory, life-threatening arrhythmias, doses as high as 480 to 640 mg per day have been used under close supervision.[7]
• For Atrial Fibrillation/Flutter: The initial dose is also 80 mg BID. The dose may be titrated upwards every 3 days as needed. The typical maintenance dose is 120 mg BID, with a maximum recommended dose of 160 mg BID for this indication.[7]
• Intravenous Dosing:
• Intravenous sotalol is used as a substitute for oral therapy in patients who are unable to take medication by mouth, or as a loading dose to more rapidly achieve therapeutic steady-state concentrations in a monitored hospital setting.[1] An intravenous dose of 75 mg is considered approximately equivalent to an 80 mg oral dose.[9] When used as a loading dose, it is typically infused over 1 hour, which can reduce the time to achieve steady-state from 3 days to 1-2 days.[1]

5.2 Protocol for Safe Initiation and Titration

The proarrhythmic risk associated with sotalol, which is highest during therapy initiation and dose escalation, has led to the establishment of a mandatory, stringent safety protocol.

• Hospitalization: The initiation or re-initiation of sotalol therapy requires hospitalization for a minimum of 3 days.[9] The facility must be equipped to provide continuous ECG monitoring and advanced cardiac life support, including cardiac resuscitation.[10]
• Baseline Assessment: Before the first dose is administered, a comprehensive baseline assessment is required. This includes a 12-lead ECG to measure the baseline QTc interval, serum creatinine to calculate the CrCl, and measurement of serum electrolytes, particularly potassium and magnesium.[15] Sotalol is contraindicated if the baseline QTc is >450 ms.[9] Any electrolyte abnormalities, especially hypokalemia or hypomagnesemia, must be corrected prior to initiation.[10]
• Titration and Monitoring: Dose increases should not occur more frequently than every 3 days to allow for the drug to reach steady-state.[23] During this period, the QTc interval must be closely monitored, typically 2 to 4 hours after each dose, which corresponds to the time of peak plasma concentration.[30] The therapy must be discontinued or the dose reduced if the QTc interval exceeds a predefined threshold, generally 500-520 ms.[7]

This procedural burden is a major factor in clinical decision-making. The choice to use sotalol is not merely a prescription but a commitment to a specific and resource-intensive care pathway involving hospitalization and intensive monitoring. Recent clinical trials investigating the safety of outpatient initiation for low-risk patients represent an attempt to challenge this long-standing paradigm, but in-hospital initiation remains the standard of care.[38]

5.3 Dose Adjustments in Special Populations

Dose adjustments are critical for specific patient populations to avoid toxicity.

• Renal Impairment: This is the most important dose modification. Since sotalol is eliminated by the kidneys, the dosing interval must be prolonged in patients with renal dysfunction. The following adjustments are standard:
• CrCl >60 mL/min: Standard dosing interval (every 12 hours).
• CrCl 40-60 mL/min: Dosing interval increased to every 24 hours.
• CrCl 10-29 mL/min: Dosing interval increased to every 36-48 hours.
• CrCl <10 mL/min: Dose must be individualized with extreme caution. For the indication of atrial fibrillation/flutter, sotalol is contraindicated if the CrCl is less than 40 mL/min.9
• Pediatrics: Dosing in the pediatric population is complex and must be determined by a specialist. It is typically calculated based on body surface area (BSA) or body weight, with initial doses of 30 mg/m² three times daily being a common starting point for children over 2 years of age.[4]
• Geriatrics: While age itself does not necessitate a dose adjustment, elderly patients frequently have a reduced creatinine clearance. Therefore, dosing in this population must be guided by their renal function, not their chronological age.[7]

5.4 Essential Monitoring Parameters

Vigilant monitoring is the cornerstone of safe sotalol therapy. The key parameters that require regular assessment are:

• ECG: Continuous monitoring during initiation and titration, with a focus on heart rate (for bradycardia) and the QTc interval (for proarrhythmic risk).[10]
• Renal Function: Serum creatinine and calculated CrCl must be monitored at baseline and periodically thereafter, especially in patients with borderline or fluctuating renal function.[10]
• Electrolytes: Serum potassium and magnesium levels should be checked at baseline and maintained within the normal range throughout therapy, as deficiencies can exacerbate QT prolongation.[10]
• Blood Pressure: Monitored for hypotension, particularly during initiation and with concomitant use of other antihypertensive agents.[10]

Table 3: Dosing Guidelines for Sotalol Based on Indication and Renal Function (CrCl)

Creatinine Clearance (CrCl)	Ventricular Arrhythmias (Oral)	Atrial Fibrillation/Flutter (Oral)	Intravenous Dosing Interval
>60 mL/min	Dose every 12 hours	Dose every 12 hours	Every 12 hours
40-60 mL/min	Dose every 24 hours	Dose every 24 hours	Every 24 hours
30-59 mL/min	Dose every 24 hours	Contraindicated (if CrCl <40)	Contraindicated (if CrCl <40)
10-29 mL/min	Dose every 36-48 hours	Contraindicated	Contraindicated
<10 mL/min	Individualize dose; use with extreme caution	Contraindicated	Contraindicated

Note: This table provides dosing intervals. The starting dose is typically 80 mg, titrated based on clinical response and QTc monitoring as described above. Always consult full prescribing information. [7]

Section 6: Safety and Tolerability Profile

The safety profile of sotalol is dominated by its cardiovascular effects, particularly its potential for life-threatening proarrhythmia. A thorough understanding of its adverse effects, contraindications, and the specifics of its Black Box Warning is essential for any clinician prescribing the medication.

6.1 Adverse Drug Reactions: A System-Organ Class Review

Sotalol is associated with a range of adverse effects, primarily related to its beta-blocking and potassium channel-blocking properties.

• Very Common (≥10% incidence): The most frequently reported adverse effects are related to beta-blockade and include fatigue (up to 20%), dizziness (up to 20%), lightheadedness (up to 12%), and asthenia (weakness, up to 13%). Bradycardia (slow heart rate) is also very common.[7]
• Common (1% to <10% incidence):
• Cardiovascular: Dyspnea (shortness of breath), chest pain, palpitations, hypotension, edema, syncope or presyncope, and congestive heart failure.[16]
• Nervous System: Headache, sleep disturbances (including insomnia and abnormal dreams), and depression.[16]
• Gastrointestinal: Nausea, vomiting, diarrhea, dyspepsia, and abdominal pain.[16]
• Other: Rash, decreased sexual performance or desire, and extremity pain.[16]
• Less Common and Rare (<1% incidence): These include mood changes, visual disturbances, hair loss or thinning, muscle cramps, and an increased sensitivity to sunburn.[19]

6.2 Black Box Warning Analysis: Proarrhythmia, QT Prolongation, and Torsade de Pointes

Sotalol carries a Black Box Warning from the FDA, the most serious warning issued by the agency, highlighting its potential to cause life-threatening ventricular arrhythmias.[6]

The central mechanism of this toxicity is its Class III effect, which prolongs the QT interval on the ECG. Excessive QT prolongation creates the electrophysiological substrate for TdP, a dangerous polymorphic ventricular tachycardia that can degenerate into ventricular fibrillation and sudden cardiac death.[5] The risk of TdP is directly related to the sotalol dose and the resulting plasma concentration.[17] The reported incidence of TdP in patients receiving oral sotalol for supraventricular arrhythmias is approximately 0.6% to 2%.[9]

The Black Box Warning emphasizes that the risk of TdP is not uniform and is significantly increased by the presence of specific risk factors:

• Higher Doses: The risk increases with dose escalation.
• Renal Impairment: Reduced creatinine clearance leads to drug accumulation, effectively creating a state of relative overdose.
• Female Sex: Women have been shown to be at higher risk for drug-induced TdP.
• Bradycardia: A slow heart rate potentiates the QT-prolonging effect due to reverse use-dependence.
• Structural Heart Disease: A history of sustained VT/VF or congestive heart failure increases risk.
• Electrolyte Imbalances: Hypokalemia (low potassium) and hypomagnesemia (low magnesium) impair the function of potassium channels and exaggerate the degree of QT prolongation.[10]

This warning is the primary driver for the strict in-hospital initiation protocols, mandating ECG monitoring and risk factor assessment before and during therapy.

6.3 Absolute and Relative Contraindications

To mitigate the risks, sotalol is contraindicated in patients where the potential for harm is unacceptably high. These contraindications are directly linked to its mechanisms of action and known risk factors.

Absolute Contraindications Include:

• Baseline Electrophysiological Abnormalities: Congenital or acquired long QT syndromes, a baseline QTc interval >450 ms, sinus bradycardia (heart rate <50 bpm), sick sinus syndrome, or second- and third-degree AV block (in patients without a functioning permanent pacemaker).[9]
• Hemodynamic Instability: Cardiogenic shock or uncontrolled/decompensated congestive heart failure.[9]
• Severe Renal Impairment: Creatinine clearance <40 mL/min for the treatment of atrial fibrillation/flutter.[9]
• Respiratory Conditions: Bronchial asthma or a history of severe bronchospastic disease, due to its non-selective β2-receptor blockade.[9]
• Electrolyte Disturbances: Uncorrected hypokalemia (<4 mEq/L) or hypomagnesemia.[22]
• Known hypersensitivity to sotalol.[16]

6.4 Management of Overdosage

Intentional or accidental overdosage with sotalol can be fatal and constitutes a medical emergency.[7] The clinical presentation is an exaggeration of its pharmacological effects. The most common signs are severe bradycardia, congestive heart failure, hypotension, bronchospasm, and hypoglycemia.[7] Massive overdoses (2-16 grams) can lead to cardiac asystole, extreme QT prolongation, TdP, and sustained ventricular tachycardia.[7]

Management is supportive and aimed at counteracting the drug's effects:

• Bradycardia/Heart Block: Atropine, other anticholinergics, beta-adrenergic agonists, or transvenous cardiac pacing.[2]
• Hypotension: Intravenous fluids and vasopressors such as epinephrine or norepinephrine.[2]
• Bronchospasm: Aminophylline or a beta-2 agonist (e.g., albuterol), often requiring higher than normal doses.[2]
• Torsade de Pointes: Immediate DC cardioversion if hemodynamically unstable, intravenous magnesium sulfate, and overdrive pacing.[2]
• Drug Removal: Due to its lack of plasma protein binding and water solubility, sotalol is effectively removed from the body by hemodialysis, which can be a life-saving intervention in cases of severe overdose.[7]

The safety profile of sotalol is notably distinct from that of other potent antiarrhythmics like amiodarone. While sotalol's primary risk is a mechanistically predictable, acute, and potentially fatal cardiac electrical event (TdP), amiodarone's toxicity is broader, affecting multiple organ systems (thyroid, liver, lungs, eyes) in a more insidious and chronic manner.[39] This fundamental difference means that risk management for sotalol is highly focused on monitoring the ECG, renal function, and electrolytes, whereas managing amiodarone requires a complex, long-term, multi-system surveillance program.

Section 7: Clinically Significant Drug and Disease Interactions

The safe use of sotalol requires a comprehensive review of a patient's concurrent medications and underlying medical conditions. The vast majority of sotalol's clinically significant drug interactions are pharmacodynamic in nature, arising from additive physiological effects rather than alterations in its metabolism.

7.1 Pharmacodynamic Interactions Increasing Proarrhythmic Risk

The most dangerous interactions are those that potentiate sotalol's QT-prolonging effect, thereby increasing the risk of TdP.

• Other QT-Prolonging Drugs: Co-administration of sotalol with other drugs known to prolong the QT interval is generally contraindicated or requires extreme caution. This includes other antiarrhythmic drugs, such as Class Ia agents (e.g., quinidine, procainamide, disopyramide) and other Class III agents (e.g., amiodarone, dofetilide, dronedarone).[16] The risk is also increased with certain non-cardiac medications, including some antipsychotics (e.g., thioridazine, haloperidol), tricyclic antidepressants, macrolide antibiotics (e.g., erythromycin), and fluoroquinolone antibiotics (e.g., moxifloxacin).[14] The combination of two or more such agents produces an additive or synergistic effect on QT prolongation.
• Electrolyte-Depleting Drugs: Medications that can cause hypokalemia or hypomagnesemia indirectly increase the risk of TdP by creating a more vulnerable electrophysiological substrate. This primarily includes loop diuretics (e.g., furosemide) and thiazide diuretics (e.g., hydrochlorothiazide).[22] Electrolyte levels must be closely monitored and corrected in patients receiving these drugs concomitantly with sotalol.

7.2 Interactions with Negative Chronotropic and Inotropic Agents

These interactions potentiate the Class II (beta-blocking) effects of sotalol, increasing the risk of bradycardia, AV block, hypotension, and heart failure.

• Other Beta-Blockers: Co-administration is generally not recommended due to additive effects.
• Non-dihydropyridine Calcium Channel Blockers: Verapamil and diltiazem have their own negative chronotropic and inotropic effects. When combined with sotalol, they can lead to severe bradycardia, AV block, and depressed ventricular function.[16]
• Digoxin: Both digoxin and sotalol slow AV conduction and heart rate. Their combined use increases the risk of significant bradycardia and AV block.[1]
• Catecholamine-Depleting Agents: Drugs such as reserpine and guanethidine can lead to an excessive reduction of resting sympathetic tone when used with a beta-blocker, potentially causing severe hypotension and bradycardia.[7]

7.3 Pharmacokinetic and Other Notable Interactions

While sotalol has no significant metabolic interactions, a few other interactions are clinically important.

• Antacids: The absorption of oral sotalol can be reduced by the concurrent administration of antacids containing aluminum or magnesium hydroxide. To avoid this interaction, these products should be taken at least 2 hours before or 2 hours after the sotalol dose.[7]
• Antidiabetic Agents: Sotalol's beta-blocking properties can interfere with glucose metabolism. It can cause hyperglycemia (particularly in type II diabetes) by inhibiting insulin secretion, and it can mask the adrenergic symptoms of hypoglycemia (such as tachycardia and tremor), making it difficult for patients to recognize a low blood sugar event. Dose adjustments of insulin or oral hypoglycemic agents may be necessary.[1]
• Beta-2 Agonists: Due to sotalol's non-selective blockade of β2-receptors, patients with asthma or COPD may require increased doses of their inhaled beta-2 agonist medications (e.g., albuterol, terbutaline) to achieve adequate bronchodilation.[1]
• Clonidine: If clonidine is to be discontinued in a patient also taking sotalol, the sotalol should be withdrawn several days prior to the gradual tapering of clonidine. This is to mitigate the risk of severe rebound hypertension that can occur from unopposed alpha-adrenergic stimulation when clonidine is withdrawn.[1]

7.4 Disease State Interactions

A patient's underlying medical conditions can significantly alter the risk-benefit profile of sotalol. Key disease interactions include:

• Renal Failure: As detailed previously, this is the most critical interaction. Sotalol accumulates in renal impairment, necessitating dose adjustment or contraindication.[27]
• Bronchospastic Diseases: Sotalol is contraindicated in patients with bronchial asthma and should be used with extreme caution in those with other bronchospastic conditions like COPD.[22]
• Heart Failure and Hypotension: Sotalol can precipitate or worsen heart failure and cause significant hypotension in susceptible individuals.[22]
• Diabetes Mellitus: Sotalol can alter glucose control and mask the signs of hypoglycemia.[27]
• Thyroid Disease: Beta-blockers can mask the cardiovascular signs of hyperthyroidism (thyrotoxicosis), such as tachycardia.[23]
• Peripheral Vascular Disease: Non-selective beta-blockade can reduce peripheral blood flow and aggravate symptoms of arterial insufficiency.[27]

Table 4: Major Drug Interactions with Sotalol and Clinical Management Recommendations

Interacting Drug / Class	Mechanism of Interaction	Clinical Consequence	Management Recommendation
Class Ia/III Antiarrhythmics (e.g., amiodarone, quinidine)	Additive QT prolongation	High risk of Torsade de Pointes (TdP)	Concomitant use is generally contraindicated or not recommended.16
Other QT-Prolonging Drugs (e.g., macrolides, fluoroquinolones, certain antipsychotics)	Additive QT prolongation	Increased risk of TdP	Avoid combination if possible. If necessary, use with extreme caution and intensive ECG monitoring.14
Non-dihydropyridine CCBs (verapamil, diltiazem)	Additive negative chronotropic and inotropic effects	Severe bradycardia, AV block, hypotension, worsening heart failure	Use with caution and close monitoring of heart rate, AV conduction, and cardiac function.16
Digoxin	Additive negative chronotropic effects (slowing of AV conduction)	Increased risk of bradycardia and AV block	Monitor heart rate and ECG closely. Proarrhythmic events may be more common.16
Potassium-Depleting Diuretics (e.g., furosemide, HCTZ)	Electrolyte depletion (hypokalemia, hypomagnesemia)	Exaggerates QT prolongation, increasing TdP risk	Monitor and correct serum potassium and magnesium levels frequently. Use with caution.22
Antacids (Aluminum/Magnesium-based)	Decreased oral absorption of sotalol	Reduced sotalol efficacy	Administer sotalol at least 2 hours before or 2 hours after the antacid dose.7
Insulin / Oral Hypoglycemics	Masking of hypoglycemic symptoms (tachycardia); potential for hyperglycemia	Unrecognized severe hypoglycemia; poor glycemic control	Counsel patients on alternative signs of hypoglycemia (e.g., sweating). Monitor blood glucose closely and adjust antidiabetic regimen as needed.1

Section 8: Comparative Analysis and Place in Therapy

Sotalol occupies a specific niche within the antiarrhythmic armamentarium. Its clinical utility is best understood through comparison with other therapeutic options and by examining its position within contemporary treatment guidelines. Its selection often represents a carefully considered decision based on a multi-domain risk stratification, positioning it between the safer but less potent pure beta-blockers and the more potent but more systemically toxic amiodarone.

8.1 Sotalol versus Amiodarone: A Head-to-Head Comparison of Efficacy and Safety

Amiodarone is often considered the most potent antiarrhythmic drug available, making its comparison with sotalol central to clinical decision-making for rhythm control, particularly in atrial fibrillation.

• Efficacy:
• Pharmacological Conversion of AF: For the acute conversion of recent-onset AF to sinus rhythm, multiple meta-analyses have found that sotalol and amiodarone have similar efficacy. Average conversion rates are approximately 47-49% for sotalol and 52% for amiodarone.[32]
• Maintenance of Sinus Rhythm: For the long-term prevention of AF recurrence, amiodarone is significantly more effective than sotalol. The landmark SAFE-T trial demonstrated a striking difference in the median time to first recurrence of AF: 487 days for patients in the amiodarone group versus only 74 days for those in the sotalol group.[32] Other studies have consistently shown that at one year of follow-up, a significantly higher percentage of patients on amiodarone remain in sinus rhythm compared to those on sotalol.[39]
• Safety and Tolerability:
• The safety profiles of the two drugs are starkly different and often drive the therapeutic choice. Sotalol's primary toxicity is cardiac and electrical in nature. Its risk of proarrhythmia, particularly TdP, is higher than that of amiodarone, which is considered to have a very low TdP risk despite significant QT prolongation.[32]
• Amiodarone, in contrast, is associated with a wide array of severe and potentially fatal non-cardiac toxicities that can develop with chronic use. These include pulmonary fibrosis, thyroid dysfunction (both hypothyroidism and hyperthyroidism), hepatotoxicity, optic neuropathy, corneal microdeposits, and skin discoloration.[39] These adverse effects are not significant concerns with sotalol therapy.
• The clinical choice, therefore, often involves a trade-off. With sotalol, the clinician accepts a higher risk of an acute, potentially lethal cardiac event (TdP) that is mechanistically predictable and can be mitigated with strict monitoring protocols. With amiodarone, the clinician accepts a lower risk of TdP but a much higher risk of long-term, cumulative, multi-organ systemic toxicity that requires extensive and ongoing surveillance.

8.2 Sotalol versus Conventional Beta-Blockers for Arrhythmia Suppression

As a non-selective beta-blocker, sotalol shares properties with conventional agents like propranolol and metoprolol. However, its additional Class III activity provides a distinct advantage in arrhythmia suppression.

A head-to-head, double-blind clinical trial directly compared sotalol (320-640 mg/day) with propranolol (120-240 mg/day) for the suppression of complex ventricular arrhythmias.[44] The results demonstrated the clear superiority of sotalol. At the final evaluation, sotalol achieved an 80% reduction in the frequency of ventricular premature complexes (VPCs), compared to only a 50% reduction in the propranolol group. Furthermore, sotalol was significantly more effective in suppressing events of ventricular tachycardia (VT).[44]

This evidence indicates that sotalol is more than just a beta-blocker. It should be considered in patients where pure beta-blockade (a Class II effect) has proven insufficient for adequate arrhythmia control. However, this increased efficacy comes with the added risks of a Class III agent, namely QT prolongation and TdP, which are not significant concerns with conventional beta-blockers like metoprolol or propranolol.

8.3 Positioning within Contemporary Antiarrhythmic Treatment Guidelines

Contemporary guidelines for the management of arrhythmias, particularly atrial fibrillation, emphasize a safety-first approach. Sotalol's place in these guidelines is carefully circumscribed by its risk profile.

• Initiation Protocol: Guidelines from major cardiology societies universally recommend that sotalol be initiated in a monitored, in-hospital setting for a minimum of 3 days to allow for assessment of its effect on the QTc interval at steady-state.[10]
• Patient Selection: Its use is generally reserved for patients with highly symptomatic arrhythmias. For atrial fibrillation, it is often considered a second-line option for rhythm control, particularly in patients without significant structural heart disease (e.g., severe left ventricular hypertrophy or low ejection fraction).[43] In patients with coronary artery disease, its safety has been debated, with some observational data suggesting an increased mortality risk compared to no antiarrhythmic therapy, but a potential benefit relative to amiodarone.[46]
• Contraindications: Guidelines strictly enforce its contraindications, especially renal impairment (CrCl <40 mL/min for AF) and a baseline prolonged QT interval.[10]

Ultimately, sotalol is positioned as a specialist agent. It is considered for patients who require more antiarrhythmic potency than a conventional beta-blocker can provide, but for whom the significant long-term systemic toxicity of amiodarone is undesirable or unacceptable (e.g., younger patients, or those with pre-existing lung, liver, or thyroid disease). The ideal candidate for sotalol has an arrhythmia severe enough to warrant the TdP risk but is otherwise healthy enough, particularly with respect to renal function and electrolyte balance, to tolerate the drug safely.

Table 5: Comparative Profile of Sotalol and Amiodarone: Efficacy, Safety, and Clinical Considerations

Attribute	Sotalol	Amiodarone
Primary Mechanism	Class II (Beta-Blockade) & Class III (IKr Blockade)	Primarily Class III; also Class I, II, & IV effects
Efficacy (AF Conversion)	Moderate; similar to amiodarone for acute conversion 32	Moderate; similar to sotalol for acute conversion 32
Efficacy (AF Maintenance)	Moderate; significantly less effective than amiodarone 32	High; considered the most effective agent for maintaining sinus rhythm 32
Primary Cardiac Toxicity	Proarrhythmia (Torsade de Pointes, dose-dependent) 22	Bradycardia, AV block; low risk of TdP 39
Key Non-Cardiac Toxicities	Primarily related to beta-blockade (fatigue, bronchospasm) 19	Extensive: Pulmonary fibrosis, thyroid dysfunction, hepatotoxicity, optic neuropathy, skin discoloration 39
Elimination Half-life	7-20 hours (prolonged in renal impairment) 1	Extremely long and variable (25-100 days) 43
Metabolism	None; 100% renal excretion 1	Extensive hepatic metabolism (CYP3A4, 2C8); many drug interactions
Initiation Protocol	Mandatory 3-day hospitalization with continuous ECG monitoring 9	Often requires a loading dose; hospitalization may be required but is not universally mandated for initiation
Key Monitoring	QTc interval, renal function (CrCl), electrolytes (K+, Mg++) 10	Thyroid function, liver function, pulmonary function, ophthalmologic exams 39

Section 9: Conclusion and Expert Insights

Sotalol remains a significant agent in the field of cardiac electrophysiology, distinguished by its unique dual-action mechanism as both a non-selective beta-blocker and a potent Class III antiarrhythmic. Its efficacy in managing life-threatening ventricular arrhythmias and maintaining sinus rhythm in highly symptomatic atrial fibrillation is well-established. However, the clinical utility of sotalol is fundamentally and perpetually constrained by its safety profile.

The primary conclusion of this comprehensive analysis is that the safe and effective use of sotalol is less a function of the drug itself and more a testament to the rigorous clinical process that must surround its administration. This process is built on three pillars:

1. Meticulous Patient Selection: The extensive list of contraindications and risk factors—particularly impaired renal function, baseline QT prolongation, electrolyte abnormalities, and severe structural heart disease—demands that only a carefully selected patient population is eligible for therapy. The decision to prescribe sotalol is an exercise in risk stratification, where the severity of the arrhythmia must justify the inherent risk of Torsade de Pointes.
2. Unwavering Adherence to Initiation Protocols: The mandated in-hospital initiation with continuous ECG monitoring is not a mere recommendation but a critical safety standard. It is a direct clinical response to the drug's pharmacokinetics and pharmacodynamics, allowing for the detection of excessive QT prolongation at steady-state, when the proarrhythmic risk is maximal.
3. Vigilant and Ongoing Monitoring: Safe long-term use requires periodic assessment of the key parameters that govern its risk: renal function (creatinine clearance), electrolyte balance (potassium and magnesium), and the QTc interval.

Sotalol occupies a precise, albeit narrow, therapeutic niche. It offers greater antiarrhythmic potency than conventional beta-blockers but avoids the extensive, multi-organ systemic toxicity associated with amiodarone. This positions it as a valuable option for specific patients, such as those who have failed pure beta-blockade but for whom the long-term risks of amiodarone are deemed unacceptable.

In conclusion, sotalol is a powerful but demanding antiarrhythmic agent. Its predictable pharmacokinetics and dual mechanism of action provide a clear therapeutic rationale for its use. However, its unforgiving dependence on renal function and its dose-dependent proarrhythmic potential necessitate a level of clinical diligence that is among the highest for any cardiovascular medication. Despite the development of newer agents, sotalol maintains an important role in the armamentarium for managing severe cardiac arrhythmias, provided its use is guided by a profound respect for its pharmacology and an uncompromising commitment to patient safety.

Works cited

1. Sotalol - StatPearls - NCBI Bookshelf, accessed August 27, 2025, https://www.ncbi.nlm.nih.gov/books/NBK534832/
2. Sotalol: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed August 27, 2025, https://go.drugbank.com/drugs/DB00489
3. Sotalol | 3930-20-9 - ChemicalBook, accessed August 27, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB6277510.htm
4. BETAPACE (sotalol HCl) - accessdata.fda.gov, accessed August 27, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019865s019lbl.pdf
5. Sotalol: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD, accessed August 27, 2025, https://www.webmd.com/drugs/2/drug-8848/sotalol-oral/details
6. Sotalol - Oral - MyHealth Alberta, accessed August 27, 2025, https://myhealth.alberta.ca/Health/medications/Pages/conditions.aspx?hwid=fdb3013
7. Reference ID: 3646806 This label may not be the latest approved by FDA. For current labeling information, please visit https://, accessed August 27, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205108s000lbl.pdf
8. Pharmacology, pharmacodynamics and pharmacokinetics of sotalol, accessed August 27, 2025, https://pubmed.ncbi.nlm.nih.gov/2403731/
9. Sotalol - accessdata.fda.gov, accessed August 27, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022306s000lbl.pdf
10. Sotalol (Betapace, Sorine) Considerations for Use - American ..., accessed August 27, 2025, https://www.acc.org/~/media/Non-Clinical/Files-PDFs-Excel-MS-Word-etc/Tools%20and%20Practice%20Support/Quality%20and%20Clinical%20Toolkits/AFib%20Toolkit/Sotalol.pdf?la=en
11. [Table, CHEMICAL FORMULA AND STRUCTURE]. - LiverTox - NCBI Bookshelf, accessed August 27, 2025, https://www.ncbi.nlm.nih.gov/books/NBK548262/table/Sotalol.T1/?report=objectonly
12. Sotalol (CAS 3930-20-9) | Glentham Life Sciences, accessed August 27, 2025, https://www.glentham.com/en/products/product/GP2987/
13. 3930-20-9 | CAS DataBase - ChemicalBook, accessed August 27, 2025, https://m.chemicalbook.com/CASEN_3930-20-9.htm
14. Sotalol - Wikipedia, accessed August 27, 2025, https://en.wikipedia.org/wiki/Sotalol
15. Sotalol Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed August 27, 2025, https://www.drugs.com/dosage/sotalol.html
16. Sotalol - Mechanism, Indication, Contraindications, Dosing, Adverse Effect, Interaction, Renal Dose, Hepatic Dose | Drug Index | Pediatric Oncall, accessed August 27, 2025, https://www.pediatriconcall.com/drugs/sotalol/959
17. Pharmacokinetic and pharmacodynamic profiles of d-sotalol and d,l-sotalol, accessed August 27, 2025, https://academic.oup.com/eurheartj/article-pdf/14/suppl_H/30/1392496/14-suppl_H-30.pdf
18. www.ncbi.nlm.nih.gov, accessed August 27, 2025, https://www.ncbi.nlm.nih.gov/books/NBK534832/#:~:text=Mechanism%20of%20Action,classification%20system%20for%20antiarrhythmic%20medications.
19. Sotalol Side Effects: Common, Severe, Long Term - Drugs.com, accessed August 27, 2025, https://www.drugs.com/sfx/sotalol-side-effects.html
20. What is the mechanism of Sotalol Hydrochloride?, accessed August 27, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-sotalol-hydrochloride
21. Showing BioInteractions for Sotalol (DB00489) | DrugBank Online, accessed August 27, 2025, https://go.drugbank.com/drugs/DB00489/biointeractions
22. Sotalol: Package Insert / Prescribing Information - Drugs.com, accessed August 27, 2025, https://www.drugs.com/pro/sotalol.html
23. Sotalol (oral route) - Side effects & dosage - Mayo Clinic, accessed August 27, 2025, https://www.mayoclinic.org/drugs-supplements/sotalol-oral-route/description/drg-20071203
24. www.mayoclinic.org, accessed August 27, 2025, https://www.mayoclinic.org/drugs-supplements/sotalol-oral-route/description/drg-20071203#:~:text=Sotalol%20may%20cause%20heart%20failure,lower%20legs%2C%20or%20weight%20gain.
25. Data Sheet - Sotalol - 27-May-2022 - Medsafe, accessed August 27, 2025, https://www.medsafe.govt.nz/profs/datasheet/s/sotaloltab.pdf
26. Abstract 16208: Population Pharmacokinetics of Intravenously and Orally Administered Sotalol in Patients With Cardiac Arrhythmias - American Heart Association Journals, accessed August 27, 2025, https://www.ahajournals.org/doi/10.1161/circ.148.suppl_1.16208
27. Sotalol Disease Interactions - Drugs.com, accessed August 27, 2025, https://www.drugs.com/disease-interactions/sotalol.html
28. CAS 3930-20-9: Sotalol | CymitQuimica, accessed August 27, 2025, https://cymitquimica.com/cas/3930-20-9/
29. Sotalol IV (sotalol hydrochloride injection 10 mL vial [15 mg/mL]), accessed August 27, 2025, https://www.sotaloliv.com/
30. Betapace, Betapace AF (sotalol) dosing, indications, interactions, adverse effects, and more - Medscape Reference, accessed August 27, 2025, https://reference.medscape.com/drug/betapace-af-sotalol-342365
31. Cardiac Arrest Completed Phase 3 Trials for Sotalol (DB00489) | DrugBank Online, accessed August 27, 2025, https://go.drugbank.com/indications/DBCOND0031003/clinical_trials/DB00489?phase=3&status=completed
32. Amiodarone vs Sotalol for Atrial Fibrillation |… | Clinician.com, accessed August 27, 2025, https://www.clinician.com/articles/83077-amiodarone-vs-sotalol-for-atrial-fibrillation
33. Comparison of sotalol versus amiodarone in maintaining stability of sinus rhythm in patients with atrial fibrillation (Sotalol-Amiodarone Fibrillation Efficacy Trial [Safe-T]) - PubMed, accessed August 27, 2025, https://pubmed.ncbi.nlm.nih.gov/12914883/
34. Atrial Arrhythmia Completed Phase Trials for Sotalol (DB00489) | DrugBank Online, accessed August 27, 2025, https://go.drugbank.com/indications/DBCOND0047980/clinical_trials/DB00489?phase=&status=completed
35. Sotalol Completed Phase Trials for Atrial Fibrillation / Arrhythmia | DrugBank Online, accessed August 27, 2025, https://go.drugbank.com/drugs/DB00489/clinical_trials?conditions=DBCOND0007740%2CDBCOND0000503&phase=&status=completed
36. Dosing & Administration - Sotalol IV - sotalol hydrcholoride injection (10 mL vial [15 mg/mL]), accessed August 27, 2025, https://www.sotaloliv.com/dosing/
37. What are the protocols for using Sotalol (beta blocker and anti-arrhythmic medication)?, accessed August 27, 2025, https://www.droracle.ai/articles/133907/protocols-for-using-sotalol
38. Study Details | Safety Assessment for Sotalol Protocol in Outpatient Unit - ClinicalTrials.gov, accessed August 27, 2025, https://www.clinicaltrials.gov/study/NCT05418036?term=Sotalol%20AND%20SOTALOL&viewType=Table&rank=1
39. Sotalol versus Amiodarone in Treatment of Atrial Fibrillation - PMC, accessed August 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5089490/
40. Sotalol Tablets (Betapace) - Cleveland Clinic, accessed August 27, 2025, https://my.clevelandclinic.org/health/drugs/20719-sotalol-tablets-betapace
41. Sotalol (intravenous route) - Side effects & uses - Mayo Clinic, accessed August 27, 2025, https://www.mayoclinic.org/drugs-supplements/sotalol-intravenous-route/description/drg-20074369
42. Amiodarone or Sotalol for Recurrent Atrial Fibrillation - AAFP, accessed August 27, 2025, https://www.aafp.org/pubs/afp/issues/1998/0901/p766.html
43. Dronedarone: an alternate choice to sotalol and amiodarone in the treatment of atrial fibrillation/flutter in patients who have coronary heart disease | EP Europace | Oxford Academic, accessed August 27, 2025, https://academic.oup.com/europace/article/16/2/153/525508
44. Sotalol Is More Powerful Than Propranolol in Suppressing Complex ..., accessed August 27, 2025, https://pubmed.ncbi.nlm.nih.gov/10684467/
45. Top sotalol alternatives and how to switch your Rx - SingleCare, accessed August 27, 2025, https://www.singlecare.com/blog/sotalol-alternatives/
46. Comparison of Safety of Sotalol Versus Amiodarone in Patients With Atrial Fibrillation and Coronary Artery Disease | Thoracic Key, accessed August 27, 2025, https://thoracickey.com/comparison-of-safety-of-sotalol-versus-amiodarone-in-patients-with-atrial-fibrillation-and-coronary-artery-disease/